MD Biosciences Blog

MCRH Wins Contract for Phase I Clinical Trial

Posted by Jared Schuster on Oct 27, 2017 9:39:51 AM

The Minnesota Clinical Research Hub has announced its first contract win for a Phase I multi-site clinical trial with a large European plasma biotherapetuics company in combination with two of its founding members, MD Biosciences and Prism Research. See the associated press release on Business Wire.

 

About the MCRH

The Minnesota Clinical Research Hub (MCRH) is a partnership of five leading companies in the Minnesota health industry collaborating to provide a comprehensive clinical development platform. Leveraging their collective expertise, Prism Research, Medtronic, Center for Diagnostic Imaging (CDI), ThreeWire and MD Bioscience provide life science companies and local clinicians with a seamless partnership ensuring a responsive, integrated approach to clinical study conduct. Further information is available at www.mncrh.com.

 

About Prism Research

Prism Research is a 52-bed clinical research company specializing in the execution and management of phase 1/2a studies in patient and healthy populations with an emphasis on complex study designs. Since 2005, Prism Research has provided FDA approved investigational pharmaceutical and medical device testing services for drug and device manufacturers, academic institutions and private physicians as well as other researchers across Minnesota, the U.S. and abroad. Further information is available at www.prismresearchinc.com.

 

About MD Biosciences

MD Biosciences is a pharmaceutical, biotechnology and diagnostics development company providing research services and advanced diagnostic capabilities to the clinical and pre-clinical research markets. As a CLIA-certified diagnostic laboratory, MD Biosciences offers a wide array of molecular, proteomic and cellular analyses across multiple sample types with biomarker experts experienced in the development and validation of custom fit-for-purpose assays. With an emphasis on inflammation, immunology, oncology, neurology, metabolic disease and pain, MD Biosciences supports the design, development and implementation of diagnostic tests for patient selection and stratification.

 

Read More

MD Biosciences Announces Launch of Salspera, LLC To Advance Saltikva® (MDB401B) Towards Regulatory Approval As Cancer Immunotherapeutic

Posted by MD Biosciences on Jul 18, 2017 3:26:21 PM

MD Biosciences is proud to announce the launch of Salspera, LLC (www.salspera.com) to advance Saltikva® (MDB401B), a microbial-based immunotherapeutic product targeting cancer, towards regulatory approval. The Salspera team is actively preparing the next clinical study phase following the successful completion of Phase 1 human safety studies. Saltikva® has been presented at high level meetings, including the most recent conference held at the NIH National Cancer Institute. Next generation programs are also advancing through the preclinical pipeline, with the goal of providing a robust palette of specialized attenuated Salmonella-based guided therapies addressing patient needs with personalized “cocktails” and adjunct therapies.

Salspera-Logo.jpg

 

About MD Biosciences

MD Biosciences is a research and development company founded in 1991 with four business divisions. MD Biosciences CLIA laboratory provides assay development and clinical testing services for clinical stage programs. MD Biosciences Preclinical Services provide contract research services for drug development in areas including immuno-oncology, CNS, inflammatory and metabolic diseases. Early stage compounds in the area of neuropathic pain and cancer are being developed through MD Biosciences Innovalora Ltd. Finally, MD Biosciences is a manufacturer and distributor of proprietary products for industrial and academic drug discovery laboratories.

 

Read More

Topics: Immuno-Oncology

NEW CLINICAL RESEARCH CONSORTIUM PROVIDES INTEGRATED DEVELOPMENT PLATFORM IN MEDICAL ALLEY

Posted by MD Biosciences on Apr 20, 2017 2:20:14 PM

Saint Paul, MN, April 20, 2017     Five leading research organizations have partnered to provide the most comprehensive clinical development platform in the industry. Leveraging their collective expertise, the Center for Diagnostic Imaging (CDI), Medtronic, MD Biosciences, Prism Research, and ThreeWire, have come together to make it easier for life science companies and clinicians to bring lifesaving and life improving products to patients in need. Dubbed the Minnesota Clinical Research Hub, this partnership provides sponsors with a flexible platform for conducting their trials, allowing use of the partners individually and collectively as research needs dictate. Contact MD Biosciences for more details about the MCRH and activities.

 

 

About MD Biosciences

MD Biosciences is a research and development company founded in 1991 with four business divisions. MD Biosciences CLIA laboratory provides assay development and clinical testing services for clinical stage programs. MD Biosciences Preclinical Services provide contract research services for drug development in areas including immuno-oncology, CNS, inflammatory and metabolic diseases. Early stage compounds in the area of neuropathic pain and cancer are being developed through MD Biosciences Innovalora Ltd. Finally, MD Biosciences is a manufacturer and distributor of proprietary products for industrial and academic drug discovery laboratories.

Read More

Topics: CRO/outsourcing, contract research, Personalized medicine, CLIA

MD Biosciences to present new advances in pig translational models for pain

Posted by MD Biosciences on Apr 20, 2017 1:38:10 PM

 

 MD Biosciences will be presenting its newest advances in translational pig models for pain at this year's SMi Pain Therapeutics Conference to be held in London, UK on May 22-23. Translational models in pigs for the study of pain have become an indispensable tool in drug development. The skin structure of the pig, particularly with respect to its neuronal structure, shows a high degree of similarity to that of humans. This provides a platform in which new therapeutics can be tested to yield results which are highly predictive of human outcomes. MD Biosciences has continuously developed its models to approximate the human condition as closely as possible, bringing its unique capabilities to the drug development process. Please contact MD Biosciences or SMi Group Ltd for conference details.

 

 

Read More

Topics: Pain, in vivo pain models, post-operative pain

MD Biosciences Expands Histology and IHC Capabilities

Posted by MD Biosciences on Mar 1, 2017 12:50:17 PM

         

 

MD Biosciences Expands Histology and IHC Capabilities

New laboratories serving growing activity on clinical assay development and analysis front

 

Weizmann Science Park, Israel, (27 February 2017) - MD Biosciences announces the expansion of its histology and IHC preclinical and clinical services. The expansion encompasses new laboratories at the Nes Ziona facility - featuring an expanded footprint, automation, plus additional new team members.

This expansion accomodates MD Biosciences' growing activity in the development of assays for novel biomarkers in preclinical, translational and clinical applications. MD Biosciences is uniquely positioned to identify and develop biomarker assays as early as preclinical phases and follow these through clinical studies. The laboratory is led by Dr. Avital Schauder and supported by a highly experienced team of scientists.

Screen Shot 2017-02-03 at 1.14.38 PM.png

About MD Biosciences

MD Biosciences is a research and development company founded in 1991 with four business divisions. MD Biosciences CLIA laboratory provides assay development and clinical testing services for clinical stage programs. MD Biosciences Preclinical Services provide contract research services for drug development in areas including immuno-oncology, CNS, inflammatory and metabolic diseases. Early stage compounds in the area of neuropathic pain and cancer are being developed through MD Biosciences Innovalora Ltd. Finally, MD Biosciences is a manufacturer and distributor of proprietary products for industrial and academic drug discovery laboratories.

 

Contact: Jane Smith

MD Biosciences Inc.
1 Imation Way          
Oakdale, MN 55128
Toll Free: 888-876-3246 or 651-641-2881
Email    

Read More

Topics: Investment, Academic Research, Research Platform, Life Science, Discovery, InnovX

MD Biosciences Announces Facility Expansions

Posted by MD Biosciences on Nov 28, 2016 11:58:26 AM

MD Biosciences Expands into New State-of-the-Art

Research Facilities                 

New Lab_Oakdale.jpg

(New research facilities to play pivotal role in Life Sciences Innovation)

St. Paul, Minn, (11.28.2016) - MD Biosciences announces its moves to new, expanded facilities in the United States and Israel. The larger research facilities will enable MD Biosciences to accommodate its growing clinical and preclinical services, its collaborative research and development activities, plus its growing drug development programs.

The new, purpose-built facilities feature state-of-the-art in vivo and in vitro laboratories, including larger space resources for CLIA proteomic and genomic analyses, and clinical flow cytometry work. The MD Biosciences histology and pathology laboratories have also been expanded to provide more complex GLP capabilities in the CNS, skin, immune-oncology and inflammatory therapeutic areas. To further accommodate specific project requirements - the new facilities also feature extensive Class 100 cleanrooms. 

As part of the new US facility, MD Biosciences will serve as the core anchor for Incubology, Inc., the new science park and incubator facility located in Oakdale, just east of Saint Paul, Minnesota. Incubology will host start-up and established companies from the pharma, medtech, chemistry and healthcare data sectors.

About MD Biosciences

MD Biosciences is a research and development company founded in 1991 with four business divisions. MD Biosciences CLIA laboratory provides assay development and clinical testing services for clinical stage programs. MD Biosciences Preclinical Services provide contract research services for drug development in areas including immuno-oncology, CNS, inflammatory and metabolic diseases. Early stage compounds in the area of neuropathic pain and cancer are being developed through MD Biosciences Innovalora Ltd. Finally, MD Biosciences is a manufacturer and distributor of proprietary products for industrial and academic drug discovery laboratories.

 

Contact: Jane Smith

MD Biosciences Inc.
1 Imation Way          
Oakdale, MN 55128
Toll Free: 888-876-3246 or 651-641-2881
Email    

Read More

Topics: Investment, Academic Research, Research Platform, Life Science, Discovery, InnovX

MD Biosciences Announces License to Colorectal Cancer Markers

Posted by MD Biosciences on Oct 14, 2016 8:53:54 AM

MD Biosciences in-licenses intellectual property assets relating to colorectal cancer diagnostic methods of Bio-Marcare Technologies

cancer-studies.jpg

(Blood-based Colon Cancer Screening Methodology)

October 14, 2016, Weizmann Science Park, Nes Ziona, Israel - MD Biosciences announced today its agreement for the exclusive license rights of all intellectual property assets of Bio-Marcare Technologies, Ltd. that relate to methods for circulating, DNA-based identification of pre-cancerous colorectal polyps and colorectal cancer. This agreement has been reached with Hadasit Medical Research Services and Development Ltd. of the Hadassah Ein Kerem Medical Center in Jerusalem, Israel.

MD Biosciences clinical scientists will be developing the methods towards commercialization at its CLIA clinical laboratories. “We are very excited to move forward with the development of the technology to provide a sensitive and cost-effective method for identifying and monitoring individuals at high risk of colorectal cancer, said Eddie Moradian, Chief Executive Officer of MD Biosciences. “A large percentage of individuals do not readily comply with current colon cancer screening methods and they would readily benefit from our blood-based tests.” 

Development work will be carried out at MD Biosciences Innovalora in Israel in conjunction with the MD Biosciences CLIA Clinical Diagnostics Laboratories in Saint Paul, MN.

About MD Biosciences

MD Biosciences is a research and development company founded in 1991 with four business divisions. MD Biosciences CLIA laboratory provides assay development and clinical testing services for clinical stage programs. MD Biosciences Preclinical Services provide contract research services for drug development in areas including immuno-oncology, CNS, inflammatory and metabolic diseases. Early stage compounds in the area of neuropathic pain and cancer are being developed through MD Biosciences Innovalora Ltd. Finally, MD Biosciences is a manufacturer and distributor of proprietary products for industrial and academic drug discovery laboratories.

Read More

Topics: Investment, Academic Research, Research Platform, Life Science, Discovery, InnovX

MD Biosciences to Present At 13th Int'l Neuroimmunology Congress

Posted by MD Biosciences on Sep 6, 2016 4:55:34 PM

St. Paul, Minn., September 6, 2016 - MD Biosciences announces its attendance at the 13th International Society of Neuroimmunology (ISNI) Congress at the International Convention Center, Jerusalem, Israel – Sept., 26-29, 2016. The ISNI congress is a biennial event which gathers neuroimmunology experts from around the world to present the latest developments and revolutions in the field.

 

 

Isaac Levi, Ph.D., Director of MD Biosciences Neurology Laboratories will present recent findings on the assessment of sensory nervous system activity in awakened MOG induced EAE animals, titled “The function of pain associated fibers in MOG induced EAE”.

MD Biosciences has over 20 years of experience in the areas of inflammation, CNS and pain, with an emphasis on the interplay between these systems. To arrange a meeting with MD Biosciences at the event, contact us at [email protected]

  

About MD Biosciences

MD Biosciences is a discovery and clinical stage pharmaceutical and biotechnological company. Over the course of 25+ years, MD Biosciences has developed a platform based on scientific expertise and knowledge, plus proprietary methodologies. Its platform is based on a deep understanding of inflammatory and immunological pathways, as well as neurological processes leading to disease states and therapeutic approaches. This knowledge is applied to the development of novel therapeutics, diagnostics as well as medical devices. MD Biosciences develops its own pipeline of compounds, develops and provides products for life science research, operates a clinical diagnostic assays laboratory and provides selective services through its contract research arm.  

Read More

Topics: Investment, Academic Research, Research Platform, Life Science, Discovery, InnovX

Preclinical Study | Microbiome Effects | Metastatic Tumor Progression

Posted by MD Biosciences on Jul 1, 2016 4:44:55 PM

4th Annual Immuno-Oncology Summit, Boston, MA

St. Paul, Minn., July 1, 2016 - MD Biosciences, announces its presence at the 4th annual Immuno-Oncology Summit at the Marriott Long Wharf, Boston, MA - Aug. 29 – Sept. 2, 2016.

Britnie James, Ph.D., Director of the MD Biosciences Immunology Laboratories will present recent data on the impact of different animal supply and the microbiome in tumor progression and treatment studies. “Understanding the Impact of Animal Vendors and the Microbiome - in Tumor Progression and Treatment - in a Model of Metastatic Breast Cancer” will be presented at 10:00 am Wed., August 31.

 

Microbiome-related Studies Screen_Shot_2016-07-01_at_4.16.13_PM.png

MD Biosciences’ recent microbiome-related studies focused on animal vendor differences in the microbiome to identify any related impact in immunological and cellular functions. “We have examined whether  animals from different vendors, with discrete microbiomes, would  present with different disease progression and therapy responses in a  murine model of metastatic breast cancer,” said Britnie James. “I will be  presenting these research findings at the Immuno-Oncology Summit.”

 

Therapeutic Progress

According to Eddie Moradian, PhD, Chief Executive of MD Biosciences, “The impact of the microbiome on disease and therapy progression is becoming more evident. The microbiome may play an important role in the preclinical setting and possibly in the clinical settings as well. We hope to contribute to the understanding of the microbiome and its intricate relation to therapeutic progress with our research.”


More Information

For more information on the upcoming event visit Immuno Oncology Summit. To arrange a meeting with MD Biosciences at the event, contact us at [email protected]


About MD Biosciences

MD Biosciences is a discovery and clinical stage pharmaceutical and biotechnological company. Over the course of 25+ years, MD Biosciences has developed a platform based on scientific expertise and knowledge, plus proprietary methodologies. Its platform is based on a deep understanding of inflammatory and immunological pathways, as well as neurological processes leading to disease states and therapeutic approaches. This knowledge is applied to the development of novel therapeutics, diagnostics as well as medical devices. MD Biosciences develops its own pipeline of compounds, develops and provides products for life science research, operates a clinical diagnostic assays laboratory and provides selective services through its contract research arm.  

Read More

Topics: Microbiome, Breast Cancer, Research Platform, Metastatic Breast Cancer, Life Science, Discovery, Metastatic tumor, Immuno-Oncology, murine model

Accelerating Academic Life Science Technology Discoveries

Posted by MD Biosciences on Jun 24, 2016 1:07:35 PM

St. Paul, Minn., June 24, 2016 - MD Biosciences launches the InnovX®lab_student.jpgresearch platform that’s designed to bridge the gap between preliminary, early stage and industry relevant life science product research discoveries by academic institute researchers, as well as de-risk necessary research investments.

InnovX® Platform Research in the focus areas of pharmaceuticals, medical devices and related biotechnologies are eligible for selection into the MD Biosciences development InnovX® Platform program. Once academic institutional researchers seeking sponsorship are accepted into the MD Biosciences program, they enter into a full partnership agreement. The partnership includes access to a large library of resources, business and technology management expertise, and a vast network of industry contacts to help accelerate innovative life science technology developments.

InnovX® - Novel Partner-based Platform

According to Eddie Moradian, Chief Executive Officer, at MD Biosciences, “The InnovX® Platform is a novel partner-based approach to selecting and advancing promising technologies to a developmental stage that’s ripe for consideration by pharmaceutical and industrial partners. MD Biosciences will invest into the developmental phase from which traditional VC’s shy away from, namely the so-called Valley of Death.” He further added, “ We believe this investment strategy will bring significant value to all parties involved and will help to bring important technologies to light which may otherwise languish due to the lack of strategic investment and funding.”

Expediting the Commercialization Process

The InnovX® Platform expedites the commercialization process of university developed assets by integrating development and entrepreneurship in multiple internal parallel projects. With our focused and lean approach, MD Biosciences will continue to invest in necessary research that will advance a technology for out-licensing, partnership or start-up formation.

The InnovX® Platform is currently in advanced discussions with a number of high-ranking academic institutions in the US and other countries.

 

About MD Biosciences

MD Biosciences is a discovery and clinical stage pharmaceutical and biotechnological company. Over the course of 25+ years, MD Biosciences has developed a platform based on scientific expertise and knowledge, plus proprietary methodologies. Its platform is based on a deep understanding of inflammatory and immunological pathways, as well as neurological processes leading to disease states and therapeutic approaches. This knowledge is applied to the development of novel therapeutics, diagnostics as well as medical devices. MD Biosciences develops its own pipeline of compounds, develops and provides products for life science research, operates a clinical diagnostic assays laboratory and provides selective services through its contract research arm.  

Read More

Topics: Investment, Academic Research, Research Platform, Life Science, Discovery, InnovX